Prestige Consumer Healthcare (PBH) Stock: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$45.45
0.68 (1.52%)
▲
5d:
-2.49%
30d:
-13.97%
90d:
-6.98%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.66
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$43.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $45.45, which is considered oversold relative to its 30-day fair value range of $45.83 to $51.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.3) compared to its historical average (11.7). Remarkably, the market is currently pricing in an annual earnings decline of 7.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is currently testing key support at $44.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $67.80 (+51.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBH is showing sideways momentum. The price is currently testing key support at $44.46. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PBH scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $67.80 (+51.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$45.83 -
$51.35
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.4% below Wall St target ($67.80)
- CAUTION: Bottoming setup, but lagging the sector by 28% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$45.83 -
$51.35
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$44.46
Resistance Level
$47.80
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.35
Wall Street Target
$67.80
(+51.4%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
-35.8%
Profit Margin
15.6%
Valuation Discount vs History
-7.2% cheaper
PE vs Historical
9.4 vs 11.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.2%
(market-implied from PE analysis)
1-Year Target
$41.55
(-7%)
2-Year Target
$38.56
(-14%)
3-Year Target
$35.78
(-20%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$44.78
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 5.5%)
$114.65
(+156%)
Base:
(SPY PE: 9.3, Growth: 5.5%)
$52.54
(+17%)
Bear:
(PE: 7.9, Growth: 5.5%)
$44.66
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.85 | Current EPS (TTM): $3.57
Bull Case
$67.68
(+51%)
Analyst growth 34.1%, PE expands to 14.1
Base Case
$61.53
(+37%)
Market implied 34.1%, PE stable at 12.9
Bear Case
$31.19
(-30%)
Severe decline -20.0%, PE contracts to 10.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.3 to 11.7
Stabilization Target:
$56.03
(+25.1%)
PE Expansion Potential:
+25.1%
Share & Embed Analysis
Last updated: October 02, 2026 2:36 PM ET
Data refreshes hourly during market hours. Next update: 3:36 PM
Data refreshes hourly during market hours. Next update: 3:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
